OrbiMed's major PIPE purchase and ownership boost drive QTTB momentum to 20% gain
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $-6.65M | $6.65M | $33.97M | $2.70M | $1.67M | $5.32M | N/A |
| Cost of Revenue | $487.00K | N/A | N/A | $9.54M | N/A | N/A | N/A | $684.21K |
| Gross Profit | $-487.00K | $-6.65M | $6.65M | $24.43M | $2.70M | $1.67M | $5.32M | $-684.21K |
| Gross Margin | 0.00% | 0.00% | 100.00% | 71.91% | 100.00% | 100.00% | 100.00% | 0.00% |
| Operating Expenses | $65.61M | $41.60M | $45.88M | $120.38M | $132.97M | $111.61M | $65.25M | $28.97M |
| Operating Income | $-66.10M | $-48.26M | $-39.23M | $-95.95M | $-130.26M | $-109.94M | $-59.93M | $-29.66M |
| Operating Margin | 0.00% | 0.00% | -589.76% | -282.44% | -4820.98% | -6599.22% | -1126.01% | 0.00% |
| Net Income | $-47.73M | $-53.74M | $-42.81M | $-95.76M | $-128.69M | $-103.92M | $-55.58M | $-29.99M |
| Net Margin | 0.00% | 0.00% | -643.65% | -281.90% | -4762.92% | -6237.45% | -1044.29% | 0.00% |
| EPS (Basic) | $-5.12 | $-16.70 | $-13.42 | $-12.23 | $-50.46 | $-44.41 | $-35.04 | $-14.42 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |